A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer
Introduction: In the absence of head-to-head trials comparing immunotherapies for advanced nonsquamous non-small-cell lung cancer (NsqNSCLC), a network meta-analysis (NMA) was conducted to compare the relative efficacy of these treatments. Materials & methods: A systematic literature review of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2023-01-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: |
| _version_ | 1827905886563074048 |
|---|---|
| author | Himani Aggarwal Kerigo Ndirangu Katherine B Winfree Catherine Elizabeth Muehlenbein Emily Zhu Vanita Tongbram Howard Thom |
| author_facet | Himani Aggarwal Kerigo Ndirangu Katherine B Winfree Catherine Elizabeth Muehlenbein Emily Zhu Vanita Tongbram Howard Thom |
| author_sort | Himani Aggarwal |
| collection | DOAJ |
| description | Introduction: In the absence of head-to-head trials comparing immunotherapies for advanced
nonsquamous non-small-cell lung cancer (NsqNSCLC), a network meta-analysis (NMA) was conducted to
compare the relative efficacy of these treatments. Materials & methods: A systematic literature review of
randomized controlled trials evaluating first-line-to-progression and second-line treatments for advanced
NsqNSCLC informed Bayesian NMAs for overall survival (OS) and progression-free survival (PFS) end points.
Results: Among first-line-to-progression treatments, pembrolizumab + pemetrexed + platinum showed
the greatest OS benefit versus other regimens and a PFS benefit versus all but three regimens. Among
second-line treatments, an OS benefit was seen for atezolizumab, nivolumab and pembrolizumab versus
docetaxel. Conclusion: Pembrolizumab + pemetrexed + platinum showed the maximum OS benefit in
the first-line setting. In the second-line setting, anti-PD-1/anti-PD-L1 monotherapies were better than
docetaxel. |
| first_indexed | 2024-03-13T00:48:15Z |
| format | Article |
| id | doaj.art-3d55849932a942438273d8c2ed031e88 |
| institution | Directory Open Access Journal |
| issn | 2042-6313 |
| language | English |
| last_indexed | 2024-03-13T00:48:15Z |
| publishDate | 2023-01-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj.art-3d55849932a942438273d8c2ed031e882023-07-08T12:37:07ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132023-01-0112210.2217/cer-2022-0016A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancerHimani Aggarwal0Kerigo Ndirangu1Katherine B Winfree2Catherine Elizabeth Muehlenbein3Emily Zhu4Vanita Tongbram5Howard Thom6Eli Lilly & Company, 893 S Delaware Street Indianapolis, IN 46225, USAICON plc, New York, NY, USAEli Lilly & Company, 893 S Delaware Street Indianapolis, IN 46225, USAEli Lilly & Company, 893 S Delaware Street Indianapolis, IN 46225, USAEli Lilly & Company, 893 S Delaware Street Indianapolis, IN 46225, USAICON plc, New York, NY, USAHealth Economics Bristol (HEB), Bristol Medical School, University of Bristol, 1-5 Whiteladies Road Clifton Bristol, BS8 1NU, United KingdomIntroduction: In the absence of head-to-head trials comparing immunotherapies for advanced nonsquamous non-small-cell lung cancer (NsqNSCLC), a network meta-analysis (NMA) was conducted to compare the relative efficacy of these treatments. Materials & methods: A systematic literature review of randomized controlled trials evaluating first-line-to-progression and second-line treatments for advanced NsqNSCLC informed Bayesian NMAs for overall survival (OS) and progression-free survival (PFS) end points. Results: Among first-line-to-progression treatments, pembrolizumab + pemetrexed + platinum showed the greatest OS benefit versus other regimens and a PFS benefit versus all but three regimens. Among second-line treatments, an OS benefit was seen for atezolizumab, nivolumab and pembrolizumab versus docetaxel. Conclusion: Pembrolizumab + pemetrexed + platinum showed the maximum OS benefit in the first-line setting. In the second-line setting, anti-PD-1/anti-PD-L1 monotherapies were better than docetaxel.immunotherapynetwork meta-analysisnonsquamous nsclcpembrolizumab |
| spellingShingle | Himani Aggarwal Kerigo Ndirangu Katherine B Winfree Catherine Elizabeth Muehlenbein Emily Zhu Vanita Tongbram Howard Thom A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer Journal of Comparative Effectiveness Research immunotherapy network meta-analysis nonsquamous nsclc pembrolizumab |
| title | A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer |
| title_full | A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer |
| title_fullStr | A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer |
| title_full_unstemmed | A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer |
| title_short | A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer |
| title_sort | network meta analysis of immunotherapy based treatments for advanced nonsquamous non small cell lung cancer |
| topic | immunotherapy network meta-analysis nonsquamous nsclc pembrolizumab |
| work_keys_str_mv | AT himaniaggarwal anetworkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT kerigondirangu anetworkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT katherinebwinfree anetworkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT catherineelizabethmuehlenbein anetworkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT emilyzhu anetworkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT vanitatongbram anetworkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT howardthom anetworkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT himaniaggarwal networkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT kerigondirangu networkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT katherinebwinfree networkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT catherineelizabethmuehlenbein networkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT emilyzhu networkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT vanitatongbram networkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer AT howardthom networkmetaanalysisofimmunotherapybasedtreatmentsforadvancednonsquamousnonsmallcelllungcancer |